News

Xiromed LLC Launches Estradiol Transdermal Gel 0.1% with a Competitive Generic Therapy (CGT) Designation

October 11, 2022

Florham Park, NJ, October 11th, 2022 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Estradiol Transdermal Gel 0.1%, generic to Divigel®.  Xiromed received final approval for its Abbreviated New Drug Application (ANDA) from the United States FDA with Competitive Generic Therapy (CGT) designation and is eligible for 180 […]


Xiromed LLC Launches Fulvestrant Injection 250 mg/5 mL (50 mg/mL)

September 12, 2022

Florham Park, NJ, September 12th, 2022 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Fulvestrant Injection 250 mg/5 mL (50 mg/mL), generic to Faslodex®. Annual market sales for Faslodex® and its generics for the twelve-month period ending July, 2022 were $101.4 million, according to IQVIA™. Rob Spina, CEO […]


Xiromed LLC Launches Progesterone Vial for Injection 500 mg/10 mL (50mg/mL)

May 2, 2022

Florham Park, NJ, May 2nd, 2022 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Progesterone Injection USP, 500 mg/10 mL (50 mg/mL) Multiple-Dose Vial, generic to Progesterone Injection USP, 50 mg/mL.   Annual market sales for Progesterone Injection USP, 50 mg/mL and its generics for the twelve month period […]


Xiromed® LLC Launches Naftifine Hydrochloride Cream USP, 2%

February 25, 2022

Florham Park, NJ, February 25th, 2022 Xiromed LLC, an Insud Pharma company, today announced the launch of Naftifine Hydrochloride Cream USP, 2%, generic to Naftin®, in partnership with Genzum Life Sciences. “Xiromed continues to execute on its growth plan to deliver quality generics to the US market. The launch of Naftifine Cream further bolsters our […]


Xiromed LLC Launches Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL)

January 24, 2022

Florham Park, NJ, January 24, 2022 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL), generic to Nitropress®. Xiromed CEO, Narasimhan Mani commented, “The launch of Sodium Nitroprusside Injection is Xiromed’s latest offering from our pipeline of injectable products and demonstrates […]


Xiromed LLC Launches Docetaxel Injection, USP, 10mg/mL

September 27, 2021

Florham Park, NJ, September 27, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Fluorouracil Injection 50mg/mL, generic to Adrucil®. Annual market sales for Adrucil® and its generics for the twelve-month period ending June, 2021 were $22.2 million, according to IQVIA™.     Xiromed CEO, Narasimhan Mani commented, “The […]


Xiromed LLC Launches Fluorouracil Injection 50mg/mL

August 12, 2021

Florham Park, NJ, August 12, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Fluorouracil Injection 50mg/mL, generic to Adrucil®. Annual market sales for Adrucil® and its generics for the twelve-month period ending June, 2021 were $22.2 million, according to IQVIA™.     Xiromed CEO, Narasimhan Mani commented, “The […]


Xiromed LLC Launches Ketoconazole Foam, 2%

August 2, 2021

Florham Park, NJ, August 2, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Ketoconazole Foam, 2%, generic to Extina®. “This is an exciting day for Xiromed as we launch our first foam product in the US market.  Xiromed is focused on expanding the range of dosage forms […]


Xiromed LLC Launches Tobramycin Vial for Injection, 1.2g

July 13, 2021

Florham Park, NJ, July 13, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Tobramycin Vial for Injection, 1.2g, generic to Nebcin®. Annual market sales for Nebcin® and its generics for the twelve month period ending April, 2021 were $16 million, according to IQVIA™.                   Xiromed CEO, […]